Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus toxoids and acellular pertussis-inactivated poliovirus vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria and tetanus toxoids and acellular pertussis-inactivated poliovirus vaccine (DTaP-IPV) is a combination vaccine designed to protect against four serious infectious diseases: diphtheria, tetanus (lockjaw), pertussis (whooping cough), and polio. The vaccine contains inactivated forms of the toxins produced by the bacteria that cause diphtheria, tetanus, and pertussis as well as inactivated poliovirus. It works by stimulating the immune system to produce antibodies against these pathogens without causing disease. This combination is administered intramuscularly to children aged 4–6 years before their seventh birthday. The primary indication is prevention of these four diseases[1][2].
- Brand names
- KinrixQuadracel
- Other names
- DTaP-IPVDTaP + IPVdiphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine
02
Targets
PV3 (Sabin) (Poliovirus type 3 antigen)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria and tetanus toxoids and acellular pertussis-inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus toxoids and acellular pertussis-inactivated poliovirus vaccine.